Preferred first-line test to diagnose inherited or acquired factor XIII (FXIII) deficiency. Appropriate for evaluation of patients with a bleeding disorder who present with normal prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count test results. Monitor FXIII therapy and confirm abnormalities detected on FXIII qualitative assay.
New York DOH Approval Status
Lt. blue (sodium citrate). Refer to Specimen Handling at www.aruplab.com for hemostasis/thrombosis specimen handling guidelines.
Transfer 2 mL platelet-poor plasma to an ARUP Standard Transport Tube. (Min: 1 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Serum. EDTA plasma, clotted or hemolyzed specimens.
Ambient: 4 hours; Refrigerated: Unacceptable; Frozen: at -20°C or below: 1 month; Frozen at -70°C or below: 3 months
Factor XIII Activity 69-143%
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2006183||Factor XIII Activity||27815-0|
- Factor 13
- fibrin stabilizing factor